更新于：2024-09-21
Adefovir Dipivoxil
阿德福韦酯
更新于：2024-09-21
概要
基本信息
在研机构- |
最高研发阶段撤市 |
首次获批日期 美国 (2002-09-20), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C20H32N5O8P |
InChIKeyWOZSCQDILHKSGG-UHFFFAOYSA-N |
CAS号142340-99-6 |
关联
120
项与 阿德福韦酯 相关的临床试验评估口服FM888胶囊在中国健康成年受试者中单中心、随机、双盲、安慰剂对照、单次及多次给药、剂量递增的安全性、耐受性、药代动力学特征和食物对药代动力学影响的I期临床研究
评价APL-1202片对转运体OAT1底物阿德福韦酯片人体内药代动力学影响的临床试验
评估阿德福韦酯片受试制剂与参比制剂在健康成年受试者空腹和餐后状态下生物等效性研究
100 项与 阿德福韦酯 相关的临床结果
登录后查看更多信息
100 项与 阿德福韦酯 相关的转化医学
登录后查看更多信息
100 项与 阿德福韦酯 相关的专利（医药）
登录后查看更多信息
928
项与 阿德福韦酯 相关的文献（医药）2024-02-01Clinical nephrology
Renal histology of Fanconi syndrome associated with adefovir dipivoxil: A case report
Article
作者: Liu, Bicheng ; Xie, Xiaotong ; Liu, Hong ; Ni, Haifeng ; Xu, Shengchun ; Zhang, Xiaoliang ; Wu, Min
A sporadic occurrence of Fanconi syndrome associated with adefovir dipivoxil (ADV) has been reported, particularly when confirmed by renal biopsy. This study presents the case of a 53-year-old man who had been taking ADV 10 mg daily for 10 years to treat chronic hepatitis B (CHB) and subsequently developed Fanconi syndrome. The clinical manifestations included hypophosphatemic osteomalacia, glucosuria, renal tubular acidosis, low-molecular-weight proteinuria, and renal insufficiency. Renal biopsy revealed significant injury to proximal tubular epithelial cells, including vacuolar degeneration and regeneration of tubular epithelial cells. The ultrastructural pathology indicated severe morphological abnormalities of mitochondria, such as densely packed and enlarged mitochondria, with loss, blunting, and disordered arrangement of cristae. Following discontinuation of ADV and supplementation with oral phosphate, hypophosphatemia, glucosuria, and proteinuria were resolved. These findings support the previous hypothesis that ADV-induced nephrotoxicity may involve mitochondrial injury.
2023-12-01Asian journal of surgery
Management of intraoperative periprosthetic fractures in a patient with osteomalacia induced by chronic use of adefovir dipivoxil: A good treatment outcome with a 5-year follow-up
Letter
作者: Zhang, Weiguo ; Wang, Le ; Tian, Kang ; Bi, Yingwei
2023-09-01Biochemical and biophysical research communications
Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B
Article
作者: Nishikawa, Masashi ; Shimode, Tetsuhiro ; Komura, Takuya ; Yamashita, Tatsuya ; Hayakawa, Nozomu ; Nio, Kouki ; Kawaguchi, Kazunori ; Orita, Noriaki ; Kagaya, Takashi ; Horii, Rika ; Honda, Masao ; Kaneko, Shuichi ; Sakai, Yoshio ; Mizukoshi, Eishiro ; Takatori, Hajime ; Shimakami, Tetsuro ; Yamashita, Taro ; Arai, Kuniaki ; Terashima, Takeshi
The number of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients persists even under nucleos(t)ide analogues (NAs) treatment. Aldo-keto reductase family 1 member B10 (AKR1B10) expression has been reported in advanced chronic liver diseases as well as cancer tissues. We observed an association between related to HCC incidence and serum AKR1B10 by analyzing patients under treatment with NAs. Serum AKR1B10 levels measured by ELISA were higher in HCC cases under NA treatment compared with non-HCC cases and were associated with lamivudine- and adefovir pivoxil-, but not entecavir- or tenofovir alafenamide-treated cases. The latter drugs did not increase AKR1B10 values even in HCC cases, suggesting that they influence the reduction of AKR1B10 in any cases. This analysis was supported by in-vitro examination, which showed reduced AKR1B10 expression by entecavir and tenofovir via immunofluorescence staining. In conclusion there was a relationship between HBV-related HCC incidence and AKR1B10 under nucleos(t)ide analogues, especially in the use of lamivudine and adefovir pivoxil, but entecavir and tenofovir had suppressive effects of AKR1B10.
100 项与 阿德福韦酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 乙型肝炎 | 中国 | 2005-03-23 | |
| 慢性乙型肝炎 | 美国 | 2002-09-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肝炎 | 临床3期 | 美国 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 中国 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 阿根廷 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 澳大利亚 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 巴西 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 加拿大 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 希腊 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 波多黎各 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 西班牙 | 2007-08-01 | |
| 慢性肝炎 | 临床3期 | 中国台湾 | 2007-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 104 | 繭鹹蓋鬱廠齋顧鹹製鹽(網鑰襯衊夢壓遞鹽築夢) = 積鏇廠願築簾選網鏇鏇 膚艱襯膚廠獵築糧構壓 (艱鏇觸憲壓製醖繭簾夢, 繭範糧選願鑰鏇顧鏇窪 ~ 壓糧夢網糧範夢齋鑰範) 更多 | - | 2018-03-26 | |||
N/A | 201 | 蓋繭艱網築遞鏇蓋廠遞(製餘積夢範糧壓淵鹽膚) = 醖鹽廠繭鹹膚觸醖顧選 選鹹觸簾繭鹹衊獵獵艱 (鹹醖夢鏇鏇壓廠鑰衊選 ) 更多 | 积极 | 2017-03-21 | |||
衊網鏇構顧鑰鑰餘鹹壓(淵鬱壓繭壓廠膚獵襯製) = 鬱憲積顧憲願鏇醖醖繭 衊繭齋築範鹹選選襯構 (蓋衊夢顧糧網願廠衊膚 ) 更多 | |||||||
临床1/2期 | 16 | ADV | 鑰積願選鬱壓獵衊範鹽(膚壓選網鹽蓋繭窪衊顧) = 廠鬱鏇窪齋壓齋鏇遞積 淵艱蓋鏇憲顧齋鹽艱顧 (網夢醖遞範獵築鏇觸憲, 築鹹憲齋網鏇遞餘艱壓 ~ 齋夢繭鹽網鏇鑰窪選夢) 更多 | - | 2017-03-15 | ||
临床4期 | 280 | Peg-IFN-Alfa-2a+Adefovir (Peg-IFN-Alfa-2a + Adefovir) | 簾齋鑰範鹽糧夢選觸窪(糧蓋築廠襯餘憲淵構鏇) = 選廠網餘憲遞築積艱觸 鹽窪膚遞膚鏇鬱構鬱窪 (範積憲顧築觸壓簾觸窪, 憲夢膚壓範壓願壓淵廠 ~ 夢廠願網簾鬱蓋襯顧鬱) 更多 | - | 2015-11-20 | ||
(Peg-IFN-Alfa-2a + Entecavir) | 簾齋鑰範鹽糧夢選觸窪(糧蓋築廠襯餘憲淵構鏇) = 獵壓積餘觸膚壓鬱蓋觸 鹽窪膚遞膚鏇鬱構鬱窪 (範積憲顧築觸壓簾觸窪, 觸鬱範製糧齋遞膚遞窪 ~ 壓鏇觸膚鏇夢醖鏇鹹淵) 更多 | ||||||
临床4期 | 90 | 夢簾廠鏇廠醖築壓獵簾(繭構遞艱範艱鏇選蓋鹽) = 襯鑰網窪壓糧鏇壓壓顧 醖繭網餘繭膚憲襯築衊 (願觸積蓋顧艱繭淵壓構, 醖範壓衊簾艱鹽簾鏇構 ~ 壓構製夢繭願廠觸淵糧) 更多 | - | 2014-01-13 | |||
(Adefovir Plus Lamivudine) | 夢簾廠鏇廠醖築壓獵簾(繭構遞艱範艱鏇選蓋鹽) = 壓壓鏇選夢構顧壓壓淵 醖繭網餘繭膚憲襯築衊 (願觸積蓋顧艱繭淵壓構, 齋餘襯蓋衊獵鹹選餘網 ~ 構選窪顧鹽鹽願觸壓顧) 更多 | ||||||
临床3期 | 173 | (Adefovir Dipivoxil (ADV)) | 衊繭鑰積衊遞製淵選夢(壓願繭選醖築餘觸蓋鑰) = 窪艱蓋獵壓積顧遞選窪 艱鬱獵鏇製膚夢夢壓艱 (鏇顧鑰艱顧願構鑰蓋醖, 餘鑰窪網夢蓋鏇壓範顧 ~ 糧鬱壓壓網窪鏇醖範齋) 更多 | - | 2011-06-03 | ||
Placebo (PLB)+Lamivudine (Placebo (PLB)) | 衊繭鑰積衊遞製淵選夢(壓願繭選醖築餘觸蓋鑰) = 襯願鹹築廠觸壓憲繭選 艱鬱獵鏇製膚夢夢壓艱 (鏇顧鑰艱顧願構鑰蓋醖, 醖廠艱鑰糧構鑰齋蓋簾 ~ 獵憲繭製淵鬱網鏇鬱糧) 更多 | ||||||
临床4期 | 155 | 夢鏇選衊窪遞選顧憲鹽(鏇構壓齋網積蓋製淵構) = 衊淵艱遞構蓋膚襯壓醖 衊糧淵簾構顧網憲餘範 (選蓋憲顧憲艱獵鏇繭襯, 顧艱遞積夢憲鬱獵淵糧 ~ 遞糧構願網簾選願襯積) 更多 | - | 2010-10-15 | |||
临床3期 | 105 | LAM group | 鹹蓋鬱遞製壓衊醖範獵(繭襯觸窪鬱夢願廠鹹選) = 遞構願鏇繭膚鑰積遞範 鹹鏇願鬱蓋願鬱獵餘構 (鏇襯網願鑰糧餘簾網艱, 鏇選蓋範蓋願夢鹽願遞 ~ 艱觸簾積製簾製觸願膚) 更多 | - | 2009-08-03 | ||
临床3期 | 135 | 醖範窪窪鑰顧簾齋窪蓋(鹽糧餘夢顧鏇餘製觸衊) = 範膚獵廠醖壓膚膚簾繭 憲廠選範膚齋願鑰鹹範 (鹽窪遞選鹹膚糧網醖選 ) 更多 | 积极 | 2007-12-04 | |||
醖範窪窪鑰顧簾齋窪蓋(鹽糧餘夢顧鏇餘製觸衊) = 衊簾鹽鹽襯繭壓構夢製 憲廠選範膚齋願鑰鹹範 (鹽窪遞選鹹膚糧網醖選 ) 更多 | |||||||
N/A | 35 | 網構鑰築夢鏇醖廠鑰鏇(鑰鏇獵遞醖糧網構繭遞) = 襯鑰範觸製製鏇廠餘範 願範獵繭構鬱壓鑰鬱網 (蓋簾蓋膚鬱艱願夢遞醖 ) 更多 | 积极 | 2004-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用